LAVA Therapeutics NVNASDAQ:LVTX
- LAST PRICE2.7000
- TODAY'S CHANGE (%)0.0600 (2.2727%)
- Bid / Lots2.6400/ 3
- Ask / Lots2.7700/ 2
- Open / Previous Close2.6300 / 2.6400
- Day Range
- 52 Week Range
- Volume33,453
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | LVTX |
|---|---|---|
| 09:32 ET | 5251 | 2.67 |
| 09:41 ET | 300 | 2.696 |
| 09:43 ET | 195 | 2.6635 |
| 09:54 ET | 3498 | 2.67 |
| 10:14 ET | 300 | 2.7 |
| 10:32 ET | 2000 | 2.6999 |
| 10:33 ET | 127 | 2.7 |
| 10:42 ET | 990 | 2.6803 |
| 10:51 ET | 200 | 2.6835 |
| 11:18 ET | 100 | 2.73 |
| 11:38 ET | 276 | 2.713 |
| 11:40 ET | 105 | 2.69 |
| 12:12 ET | 600 | 2.72 |
| 12:14 ET | 150 | 2.73 |
| 12:27 ET | 200 | 2.7101 |
| 12:39 ET | 293 | 2.73 |
| 12:43 ET | 100 | 2.7147 |
| 12:50 ET | 100 | 2.71 |
| 01:14 ET | 100 | 2.73 |
| 01:32 ET | 200 | 2.7453 |
| 01:33 ET | 100 | 2.72 |
| 03:20 ET | 100 | 2.72 |
| 03:39 ET | 400 | 2.74 |
| 03:41 ET | 100 | 2.7343 |
| 03:52 ET | 3346 | 2.67 |
| 03:54 ET | 800 | 2.66 |
| 03:56 ET | 910 | 2.67 |
| 03:57 ET | 3110 | 2.6414 |
| 03:59 ET | 5343 | 2.7 |
May 6, 2024
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference, from 4:05PM ET on Monday May 06, 2024 by Dow Jones
4:05PM ET on Monday May 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
LAVA Therapeutics NV | 69.4M | -1.7x | --- |
Kronos Bio Inc | 61.3M | -0.5x | --- |
Kezar Life Sciences Inc | 55.7M | -0.5x | --- |
Atara Biotherapeutics Inc | 73.5M | -0.3x | --- |
Ikena Oncology Inc | 69.0M | -0.9x | --- |
Curis Inc | 69.6M | -1.2x | --- |
Company Information
LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
Contact Information
- Headquarters
- Yalelaan 60UTRECHT, Netherlands 3584 CM
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Chairman of the Board
- Kapil Dhingra
- President, Chief Executive Officer, Management Director
- Stephen Hurly
- Chief Financial Officer
- Edward Smith
- Executive Vice President Head of Research and Development
- Paul Parren
- Chief Scientific Officer
- Hans Van Der Vliet
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $69.4M |
|---|---|
Revenue (TTM) | $6.8M |
Shares Outstanding | 26.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.58 |
Book Value | $1.95 |
P/E Ratio | -1.7x |
Price/Sales (TTM) | 10.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -638.99% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
